Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering

American Journal of Cardiology

Volumn 102, Issue 12 SUPPL., 2008, Pages 41L-47L

  Jones, Peter H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID PLUS ICOSAPENTAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; METABOLIC SYNDROME X; NIACIN; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; VITAMIN B COMPLEX;

EID: 57649093994     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.074     Document Type: Article

References (69)

1. Geiss L.S., Wang J., and Gregg E.W. Long term trends in the prevalence and incidence of diagnosed diabetes. Presented at: the 67th Annual American Diabetes Association Scientific Sessions; June 22-26,; Chicago, Illinois. Abstract 0125-OR. (2007)
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
3. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., and Cowie C.C. Mortality trends in men and women with diabetes, 1971-2000. Ann Intern Med 147 (2007) 149-155
4. Fox C.S., Coady S., Sorlie P.D., D'Agostino Sr. R.B., Pencina M.J., Vasan R.S., Meigs J.B., Levy D., and Savage P.J. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115 (2007) 1544-1550
5. International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. IDF Web site. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf Published 2006. Accessed January 24, 2008
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
7. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
8. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., et al., American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
9. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
10. Grundy S.M., Hansen B., Smith Jr. S.C., Cleeman J.I., Kahn R.A., American Heart Association, National Heart, Lung, and Blood Institute, and American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 109 (2004) 551-556
11. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R., and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
12. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol 102 suppl (2008) 19L-27L
13. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
16. Sever P.S.S., Dahlöf B., Poulter N., Wedel H., Beevers G., Caufield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
17. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K., and Treating to New Targets Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
18. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., Hsia J., Breazna A., LaRosa J., Grundy S., and Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
19. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
20. Goldberg R.B., Mellies M.J., Sacks F.M., Moyé L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., and Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98 (1998) 2513-2519
21. Pyörälä K., Ballantyne C.M., Gumbiner B., Lee M.W., Shah A., Davies M.J., Mitchel Y.B., Pedersen T.R., Kjekshus J., and Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 (2004) 1735-1740
22. Girman C.J., Rhodes T., Mercuri M., Pyörälä K., Kjekshus J., Pedersen T.R., Beere P.A., Gotto A.M., Clearfield M., and 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
23. Ballantyne C.M., Herd A., Ferlic L.L., Dunn J.K., Farmer J.A., Jones P.H., Schein J.R., and Gotto Jr. A.M. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99 (1999) 736-743
24. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., Fruchart J.C., and Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
25. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
26. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., Boekholdt M.S., Khaw K.-T., and Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
27. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner H., Shepherd J., Waters D.D., and Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
28. Feher M.D., Caslake M., Foxton J., Cox A., and Packard C.J. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 15 (1999) 395-399
29. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., Hamsten A., Taskinen M.R., and DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation 107 (2003) 1733-1737
30. Tenkanen L., Mantarri M., and Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 92 (1995) 1779-1785
31. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., and Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
32. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 1154-1161
33. Scott R., d'Emden M., Best J., Drury P., Ehnholm C., Kesaniemi A., Pardy C., Tse D., Barter P., Taskinen M.R., Copt S., Keech A., and FIELD Investigators. Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. II-838. Circulation 116 (2007) Abstract 3691
34. Tenkanen L., Mänttäri M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
35. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glosziou P., et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD trial): randomised controlled trial. Lancet 366 (2005) 1849-1861
36. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
37. McKenney J.M., Jones P.H., Bays H.E., Knopp R.H., Kashyap M.L., Ruoff G.E., and McGovern M.E. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
38. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
39. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
40. Clinical Trial: AIM HIGH: Niacin plus statin to prevent vascular events. www.clinicaltrials.gov.ct/show/NCT00120289 Accessed January 6, 2008
41. Clinical Trial: HPS2-THRIVE. Treatment of HDL to reduce the incidence of vascular events. www.clinicaltrialsgov.ct/show/NCT00461 Accessed January 6, 2008
42. Buse J.B., Bigger J.T., Byington R.P., Cooper L.S., Cushman W.C., Friedewald W.T., Genuth S., Gerstein H.C., Ginsberg H.N., Goff Jr. D.C., et al., ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 suppl (2007) 21i-33i
43. Manuel D.G., and Schultz S.E. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 27 (2004) 407-414
44. Wandell P.E. Quality of life of patients with diabetes mellitus: an overview of research in primary health care in the Nordic countries. Scand J Prim Health Care 23 (2005) 68-74
45. Dodson P.M., Galton D.J., and Winder A.F. Retinal vascular abnormalities in the hyperlipidemias. Trans Ophthalmol Soc UK 101 (1981) 17-21
46. Chew E.Y., Klein M.L., Ferris III F.L., Remaley N.A., Murphy R.P., Chantry K., Hoogwerf B.J., and Miller D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: ETDRS Report 22. Arch Ophthalmol 114 (1996) 1079-1084
47. Chowdhury T.A., Hopkins D., Dodson P.M., and Vafidis G.C. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid-lowering therapy?. Eye 16 (2002) 689-693
48. Lyons T.J., Jenkins A.J., Zheng D., Lackland D.T., McGee D., Garvey W.T., and Klein R.L. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45 (2004) 910-918
49. Ucgun N.I., Yildirim Z., Kilic N., and Gursel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 100 (2007) 213-217
50. Mogensen C.E., and Poulsen P.L. Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl 92 (2004) S40-S41
51. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
52. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 102 suppl (2008) 34L-40L
53. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., Taskinen M.R., Simes R.J., Tse D., Williamson E., et al., FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
54. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493
55. Steiner G. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol 102 suppl (2008) 28L-33L
56. Burgess D., Hunt D., Li L.P., Zhang J., Sy R., Laakso M., Davis T., Colman P., Forder P., Williamson E., Pike R., Keech A., and FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [abstract]. Circulation 116 (2007) II-838
57. Chew E.Y., Ambrosius W.T., Howard L.T., Greven C.M., Johnson S., Danis R.P., Davis M.D., Genuth S., Domanski M., and ACCORD Study Group. Rationale, design and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol 99 suppl (2007) 103i-111i
58. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., Kostis J.B., Sheps D.S., and Brinton E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease The ADMIT study: a randomized trial. JAMA 284 (2000) 1263-1270
59. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., Ganda O.P., Rosenson R.S., Buse J.B., Robertson D.D., Sheehan J.P., and Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 162 (2002) 1568-1576
60. Guyton J.R., and Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 99 suppl (2007) 22C-31C
61. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 suppl (2007) 3C-18C
62. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
63. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
64. Corsini A., Bellosta S., and Davidson M.H. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 96 suppl (2005) 44K-49K
65. Minihane A.M., Khan S., Leigh-Firbank E.C., Talmud P., Wright J.W., Murphy M.C., Griffin B.A., and Williams C.M. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20 (2000) 1990-1997
66. Montori V.M., Farmer A., Wollan P.C., and Dinneen S.F. Fish oil supplementation in type 2 diabetes: a quantitative systemic review. Diabetes Care 23 (2000) 1407-1415
67. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. results of the GISS-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infartio miocardico. Lancet 354 (1999) 447-455
68. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Itakura H., et al., Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098
69. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.W., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372